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Abstract
Introduction: Disease remission has become a feasible goal for most rheumatoid arthritis (RA) patients; however,
patient-reported symptoms, such as pain, may persist despite remission. We assessed the prevalence of pain in RA
patients in remission according to the Disease Activity Score (DAS28-CRP4) and the American College of
Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria.
Methods: Data were analyzed from RA patients in the Brigham Rheumatoid Arthritis Sequential Study with data at
baseline and 1 year. DAS28 remission was defined as DAS28-CRP4 <2.6. The ACR/EULAR remission criteria included
(a) one or more swollen joints, (b) one or more tender joints, (c) C-reactive protein ≤1 mg/dl, and (d) patient
global assessment score ≤1. Pain severity was measured by using the pain score from the Multi-Dimensional
Health Assessment Questionnaire (MDHAQ). The associations between baseline clinical predictors and MDHAQ pain
at baseline and 1 year were assessed by using multivariable linear regression.
Results: Among the 865 patients with data at baseline and 1 year, 157 (18.2%) met DAS28-CRP4 remission criteria at
both time points. Thirty-seven (4.3%) met the ACR/EULAR remission criteria at baseline and 1 year. The prevalence of
clinically significant pain (MDHAQ pain ≥4) at baseline ranged from 11.9% among patients meeting DAS28-CRP4
remission criteria to none among patients meeting ACR/EULAR remission criteria. Patient global assessment, MDHAQ
function, MDHAQ fatigue, MDHAQ sleep, and arthritis self-efficacy were significantly associated with MDHAQ pain in
cross-sectional (P ≤ 0.0005) and longitudinal analyses (P ≤ 0.03). Low swollen-joint counts were associated with high
MDHAQ pain in longitudinal analyses (P = 0.02) but not cross-sectional analyses. Other measures of inflammatory
disease activity and joint damage were not significantly associated with MDHAQ pain at baseline or at 1 year.
Conclusions: Clinically significant pain continues among a substantial proportion of patients in DAS28 remission
but not among those in ACR/EULAR remission. Among patients in DAS28 remission, patient global assessment,
disability, fatigue, sleep problems, and self-efficacy are strongly associated with pain severity at baseline and 1 year,
whereas inflammatory disease activity and joint damage are not significantly associated with elevated pain severity
at either baseline or 1 year.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease that causes significant pain and disability. Sixty-
eight percent of RA patients rate pain as their highest
priority for improvement, and 90% of RA patients rate
pain as one of their top three priorities [1]. With the
earlier initiation of disease-modifying therapies and the
development of targeted immunomodulating agents [2],
an increasing number of RA patients are able to achieve
minimal disease activity, and some are able to achieve
complete disease remission [3-5]. However, on a popula-
tion level, mean pain ratings have remained the same
over the past 20-year period [6], and 82% of RA patients
who consider their disease to be “somewhat to
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severe pain levels [7].
In a study of Disease Activity Score (DAS28) remission
in the Arthritis and Rheumatology Clinic of Kansas and
the Rheumatoid Arthritis Evaluation Study databases,
mean and median pain scores were 2.43 and 1.50 on a 0-
to-10 visual analogue pain scale [8]. Although these
values were relatively low, they were higher than the cut-
point of 1.25, which separated patients who were satisfied
with their health from those who were not. This observa-
tion indicated that, even among patients in DAS28 remis-
sion, many still have enough pain to negatively affect
health satisfaction. It was not clear whether this pain was
due to residual inflammatory disease activity or whether
this pain was not inflammatory.
Presented with a patient with tender joints and/or pain
but no other evidence for inflammatory disease, physicians
must decide whether to escalate or add other disease-
modifying therapy. If they decide not to increase immuno-
modulation, they are left with the dilemma of how to
address the pain. Currently, very little data exist to guide
this treatment decision. The American College of Rheu-
matology (ACR)/European League Against Rheumatism
(EULAR) consensus conference for the definition of remis-
sion recognized the potential impact of non-inflammatory
causes of pain and called for studies to investigate the role
of non-RA pain among patients in remission [9].
In this article, we examine the prevalence of clinically
significant pain among RA patients in remission accord-
ing to the DAS28-CRP4 and the ACR/EULAR criteria.
Among patients who met the DAS28-CRP4 criterion for
remission, we also assess whether pain severity is asso-
ciated with inflammation or other factors, such as fati-
gue and sleep problems, which may be indicative of a
non-inflammatory chronic widespread pain syndrome.
Materials and methods
Study population
The primary cohort includes the 157 RA patients in the
Brigham and Women’s Hospital Rheumatoid Arthritis
Sequential Study (BRASS) who met DAS28-CRP4 remis-
sion criteria [10,11] at both study entry and 1-year fol-
low-up. BRASS is an observational, hospital-based
cohort of 1,118 individuals with established RA. Inclu-
sion criteria include age 18 years or older and a diagno-
sis of RA made by a board-certified rheumatologist.
Additional details can be found in a past publication
[12]. The Partners Institutional Review Board approved
the study, and written informed consent was obtained
from all participants.
Remission definitions
The DAS28-CRP4 was calculated from the tender-joint
count, swollen-joint count, C-reactive protein (CRP),
and patient global assessment [13]. DAS28-CRP4 remis-
sion was defined as a score <2.6 [10]. To satisfy the
ACR/EULAR remission criteria, participants had to
have: 1) ≤1s w o l l e nj o i n t ,2 )≤1t e n d e rj o i n t ,3 )C R P≤1
mg/dl, and 4) patient global assessment score ≤1 (of 10)
[14]. The patient global score was taken from the Multi-
Dimensional Health Assessment Questionnaire
(MDHAQ) item stating, “Considering all the ways that
your illness affects you, rate how you are doing.”
Study procedures
Participants provided demographic and clinical informa-
tion, including detailed lists of comorbidities and medi-
cation histories. A modified Charlson comorbidity index
was constructed by using available data [15]. Hemiplegia
and peripheral vascular disease were omitted from the
index because these data were not collected. We also
did not have data to distinguish between mild liver dis-
ease and moderate/severe liver disease, uncomplicated
diabetes versus diabetes with end-organ damage, and
metastatic versus nonmetastatic tumors. In these cases,
point values were assigned based on the less-severe con-
dition (for example, all cases of liver disease were
assigned 1 point; all cases of diabetes were assigned 1
point; all tumors were assigned 2 points).
Samples of blood were collected for a standard
laboratory panel, including the CRP. Baseline hand
radiographs were obtained, and Sharp scores were cal-
culated based on joint-space narrowing and erosions.
A physician performed a 28-joint count and assess-
ment of disease activity. Participants also completed
the MDHAQ, Mental Health Index-5 (MHI5) and the
Arthritis Self Efficacy Scale (ASES). The MDHAQ is a
validated instrument that includes assessments of pain,
fatigue, and function, scored on 0-to-10 scales (high
scores indicate more pain, more fatigue, and poor
function) [16]. Specifically, the MDHAQ asks, “How
much pain have you had because of your illness in the
past week?” and “How much of a problem has fatigue
or tiredness been for you in the past week?” The
MDHAQ also includes a question regarding sleep pro-
blems, scored on a 0-to-3 scale (high scores indicate
more sleep disturbances). The MHI5 is a validated
five-item assessment of mental health, scored on a 1-
to-100 scale (high scores indicate good mental health).
The ASES is scored on a 10-to-100 scale (high scores
indicate more self-efficacy) [17].
Statistical analyses
Means and standard deviations (SDs) were calculated for
normally distributed variables. Median values and inter-
quartile ranges (IQRs) were determined for variables
that were not normally distributed. Continuous indepen-
dent variables were categorized based on tertiles.
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cant pain was defined as an MDHAQ pain score ≥4.
This threshold was determined based on literature
reports requiring pain-severity levels ≥4o f1 0o r4 0o f
100 for inclusion in clinical trials of pain medications to
treat painful conditions, including arthritis [18].
Multivariable associations between baseline clinical
variables and baseline MDHAQ pain score were exam-
ined by using multivariable linear regression. All multi-
variable models were adjusted for age and gender. The
same methods were used to examine the longitudinal
relation between baseline clinical variables and 1-year
pain severity, except, in the primary multivariable ana-
lyses, baseline MDHAQ pain score was also included as
a covariate. Secondary analyses were also conducted,
adjusting for age and gender but excluding baseline
MDHAQ pain score as a covariate. All statistical ana-
lyses were performed by using the SAS 9.2 software
package (SAS Institute, Cary, NC, USA).
Results
At baseline, the prevalence of DAS28-CRP4 remission
was 24.9%, and the prevalence of ACR/EULAR remis-
sion was 8.8% among the 1,118 individuals in the
BRASS cohort. The prevalence of remission did not dif-
fer significantly between those with 1-year follow-up
data (25.3% met DAS28-CRP4 criteria; 8.6% met ACR/
EULAR criteria) and those who were lost to follow-up
(17.1% met DAS28-CRP4 criteria; 13.0% met ACR/
EULAR criteria).
Among the 865 patients with both baseline and 1-year
data, 157 (18.2%) patients remained in sustained
DAS28-CRP4 remission at both baseline and 1 year
(Figure 1). Thirty-seven (4.3%) also met ACR/EULAR
criteria for remission at baseline and 1 year. All patients
who met ACR/EULAR revised criteria for remission also
met DAS28-CRP4 remission criteria.
Baseline characteristics of patients in sustained remission
Among the 157 patients in sustained DAS28-CRP4
remission, mean age was 51.8 years; 135 (86.0%) were
female patients (Table 1). Median disease duration was
6 years (IQR 2.0, 17.0), and 113 (72.4%) were seroposi-
tive. The median MHI5 score was 80.0 (IQR 70.0, 90.0)
on a scale of 0 to 100, with 100 being perfect mental
health. The median MDHAQ fatigue score was 2.5 (IQR
1.0, 5.0) on a scale of 0 to 10, with 10 being severe fati-
gue. Eighty-two participants (52.2%) were taking metho-
trexate; 71 (45.2%) were taking a biologic disease-
modifying antirheumatic drug (DMARD), and 22
(14.0%) were taking a nonmethotrexate, nonbiologic
DMARD. Thirty-six (22.9%) were taking a combination
of methotrexate and a biologic DMARD. Four (2.6%)
were taking a combination of methotrexate and a
nonmethotrexate, nonbiologic DMARD, and seven
(4.5%) were taking a combination of a biologic DMARD
and a nonmethotrexate, nonbiologic DMARD. Eighty
(51.0%) were taking nonsteroidal anti-inflammatory
drugs, eight (5.1%) were taking opioid pain medications,
and 16 (10.2%) were taking other pain medications (for
example, tramadol and acetaminophen).
Pain severity at baseline and 1 year
Among patients in sustained DAS28-CRP4 remission,
the distribution of MDHAQ pain scores was skewed at
baseline and 1 year, with the majority of patients having
MDHAQ pain scores ≤2 (Figure 2). At baseline, 11.9%
had MDHAQ pain scores ≥4, and 12.5% had MDHAQ
pain scores ≥4 at 1 year. None of the 37 patients in sus-
tained ACR remission had a MDHAQ pain rating ≥4a t
baseline, and only two (5.7%) had MDHAQ pain ratings
≥4 at 1 year.
Cross-sectional associations between baseline clinical
variables and baseline pain
In multivariable analyses adjusted for age and gender,
baseline patient global assessment ratings (P < 0.0001)
and MDHAQ function scores (P < 0.0001) were the
only disease-related variables significantly associated
with high baseline MDHAQ pain scores (Table 2). Swol-
len-joint count, tender-joint count, and CRP were not
significantly associated with MDHAQ pain scores. Sleep
and psychosocial variables, including the baseline
MDHAQ fatigue score (P < 0.0001) and the MDHAQ
Figure 1 Study disposition. Flow diagram of the number of
participants included in this study. ACR, American College of
Rheumatology; BRASS, Brigham and Women’s Hospital Rheumatoid
Arthritis Sequential Study; DAS28, disease activity score in 28 joints;
DAS28-CRP4, disease activity score in 28 joints calculated by using
CRP and patient global assessment; EULAR, European League
Against Rheumatism.
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ciated with high baseline MDHAQ pain scores. Lower
ASES scores (P = 0.0005) and MHI scores (P = 0.004)
were also significantly associated with high baseline
MDHAQ pain scores.
Longitudinal analyses examining associations between
baseline clinical variables and pain at 1 year
In multivariable analyses adjusted for age, gender, and
baseline MDHAQ pain score, baseline MDHAQ func-
tion score (P = 0.008), disease duration (P =0 . 0 2 ) ,a n d
patient global assessment (P =0 . 0 3 )w e r et h eo n l yd i s -
ease-related variables positively associated with
MDHAQ pain scores at 1 year. Baseline swollen-joint
count was negatively associated with MDHAQ pain
scores at 1 year (P = 0.02). Baseline MDHAQ fatigue
score (P = 0.0001), MDHAQ sleep-problems score (P =
0.001), and ASES score (P = 0.01) were all significantly
associated with 1-year MDHAQ pain score (Table 3). In
secondary analyses, excluding baseline MDHAQ pain
score as a covariate, baseline patient global assessment,
baseline MDHAQ function score, baseline MDHAQ
fatigue score, baseline MDHAQ sleep-problems score
and baseline ASES score all remained significantly asso-
ciated with 1-year MDHAQ pain score (P < 0.0001).
Discussion
Among patients in sustained DAS28-CRP4 remission for
longer than 1 year, the prevalence of clinically signifi-
cant pain was 11.9% at baseline and 12.5% at 1 year. No
markers of inflammatory activity were associated with
increased pain severity at baseline or 1 year. Patient glo-
bal assessment, disability, fatigue, sleep problems, and
self-efficacy were strongly associated with pain at both
baseline and 1 year.
Although rheumatologists and patients typically think
of RA remission as a painless state [19-21], our study
shows that remission does not always equal a pain-free
state. These findings are significant because pain is con-
sidered the most important patient-reported outcome in
rheumatology [22], yet it persists in >10% of patients
who are classified in remission by DAS28-CRP4 criteria.
The cause of pain in these patients may arise from
inflammation, structural joint damage, and/or non-dis-
ease-related factors. Our data suggest that inflammation
and structural joint damage are not major causes of
pain, because CRP, swollen-joint count, tender-joint
count, and Sharp scores were not significantly associated
with increased pain severity at baseline or 1 year. How-
ever, patient global assessment and MDHAQ function
scores were strongly associated with increased pain
severity at baseline and 1 year. Disease duration was
Table 1 Baseline characteristics of the 157 RA patients in
sustained DAS28-CRP4 remission (at baseline and 1 year)
Clinical characteristics Values
Demographic variables
Age, years, mean (SD) 51.8 (14.0)
Female (%) 135 (86.0)
Caucasian (%) 145 (93.6)
Married/significant other (%) 112 (71.3)
Lives alone (%) 19 (14.1)
Ever smoker (%) 58 (39.2)
Body mass index, kg/m
2, mean (SD) 25.0 (4.4)
Modified Charlson index (range, 0-23) 1.0 (0.0, 2.0)
Disease variables
Disease duration, years 6.0 (2.0, 17.0)
Rheumatoid Factor/Anti-CCP positive (%) 113 (72.4)
Tender-joint count 0.0 (0.0, 0.0)
Swollen-joint count 0.0 (0.0, 2.0)
C-reactive protein, mg/L 1.2 (0.5, 2.7)
Patient global assessment (range, 0-10) 1.0 (0.0, 2.0)
DAS28-CRP4, mean (SD) 1.8 (0.4)
Total Sharp score (range, 0-448) 4.0 (0.0, 29.0)
Multi-Dimensional Health Assessment Function
(range, 0-10)
0.3 (0.0-1.0)
Multi-Dimensional Health Assessment Pain
(range, 0-10)
1.0 (0.5 2.5)
Psychiatric distress/Sleep variables
Mental Health Index-5 (range, 0-100) 80.0 (70.0,
90.0)
Multi-Dimensional Health Assessment Sleep (range,
0-3)
1.0 (0.0, 1.0)
Multi-Dimensional Health Assessment Fatigue
(range, 0-10)
2.5 (1.0, 5.0)
Arthritis Self-efficacy (range, 10-100) 82.5 (70.0,
90.0)
Medications
Prednisone (%) 31 (19.8)
MTX (%) 82 (52.2)
bDMARD (%) 71 (45.2)
Non-MTX, non-bDMARD (%) 22 (14.0)
Combination MTX and bDMARD (%) 36 (22.9)
Combination MTX and non-MTX, non-bDMARD (%) 4 (2.6)
Combination bDMARD and non-MTX,
non-bDMARD (%)
7 (4.5)
Nonsteroidal anti-inflammatory drugs (%) 80 (51.0)
Opioids (%) 8 (5.1)
Other pain medications (%) 16 (10.2)
anti-CCP, anti-cyclic citrullinated peptide; bDMARD, biologic DMARD; DAS28-
CRP4, disease activity score in 28 joints calculated by using CRP and patient
global assessment; MTX, methotrexate; RA, rheumatoid arthritis; SD, standard
deviation. Continuous variables are listed as medians (interquartile ranges),
and dichotomous variables are listed as numbers (%), unless otherwise noted.
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although not at baseline.
The patient global assessment and MDHAQ function
scores are often interpreted as measures of RA-related
joint inflammation and damage, but these measures also
reflect a wide range of non-inflammatory factors. Other
s t u d i e sh a v er e p o r t e dt h a tt h ee x p l a i n e dv a r i a n c ei n
patient global scores by inflammation is low (6.7%) [23],
and MDHAQ function scores are elevated in a wide
range of other conditions, including fibromyalgia, a non-
inflammatory condition that is not associated with joint
damage [24]. RA patients with fibromyalgia have signifi-
cantly worse physical function compared with RA
patients without fibromyalgia, even though sedimenta-
tion rates are only marginally higher [25]. Given these
observations and the lack of association between Sharp
scores, CRP, swollen-joint count, tender-joint count, and
high MDHAQ pain scores, we believe that the associa-
tions between patient global assessment/MDHAQ func-
tion and MDHAQ pain may be attributed to non-RA-
related factors, and that the likelihood that inflammation
and joint damage are major contributors to pain is low.
The association between disease duration and 1-year
MDHAQ pain may reflect joint damage that accrues
with increasing disease duration, or it may reflect time-
dependent changes in pain processing that lead to a
hyperalgesic state. However, disease duration was not
significantly associated with baseline MDHAQ pain.
This finding weakens the argument that disease duration
acts as a proxy for joint damage and raises the
Figure 2 Distribution of MDHAQ pain scores at baseline and 1 year. The numbers depicted are among (a) RA patients in DAS28-CRP4
remission (n = 157), and (b) RA patients in ACR/EULAR remission (n = 37). ACR, American College of Rheumatology; DAS28-CRP4, disease
activity score in 28 joints calculated by using CRP and patient global assessment; EULAR, European League Against Rheumatism; MDHAQ, Multi-
Dimensional Health Assessment Questionnaire; RA, rheumatoid arthritis.
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and 1-year MDHAQ pain may be attributable to chance.
Alternatively, these observations are compatible with the
hypothesis that increased pain is due to a hyperalgesic
state, such as fibromyalgia, that is established and/or
enhanced between the baseline and 1-year visits.
The strong association between baseline fatigue, sleep
problems, poor self-efficacy, and baseline and 1-year
pain severity also supports the existence of an enhanced,
non-inflammatory pain state among these patients with
pain despite DAS28-CRP4 remission. Fatigue, sleep pro-
blems, and poor self-efficacy are part of a noninflamma-
tory symptom cluster associated with “symptom
intensification” syndromes [26-28]. These syndromes
encompass conditions such as fibromyalgia, which mani-
fest with a broad range of symptoms, including wide-
spread pain, fatigue, sleep problems, and cognitive
difficulties. The etiology of these syndromes is unclear
but may be associated with deficits in central pain-pro-
cessing mechanisms, such as central sensitization, that
result in hyperalgesia and allodynia [26]. Thus, thera-
peutic strategies targeted toward correcting central pain
mechanisms and improving sleep and self-efficacy may
be more effective at decreasing pain than strategies
focused on intensifying disease-modifying therapies.
Limitations of this study include the use of the
DAS28-CRP4 threshold of 2.6 as the primary criterion
for remission. Although the DAS28-CRP4 remission cri-
terion is the most commonly used definition for remis-
sion, it is not a perfect measure of inflammatory disease
activity. Critics have noted that the DAS28-CRP4 remis-
sion threshold of 2.6 permits patients to have multiple
tender and swollen joints [29]. In this study, the maxi-
mum number of tender joints was three, and the maxi-
mum number of swollen joints was 10, confirming these
assertions. However, neither tender-joint count nor
swollen-joint count was significantly associated with
pain severity in cross-sectional analyses. In longitudinal
analyses, swollen-joint count was associated with low
pain levels, rather than high pain levels. Together with
the finding that CRP levels were not significantly asso-
ciated with pain scores, these observations argue against
Table 2 Cross-sectional associations between baseline
clinical variables and baseline MDHAQ pain, adjusted for
age and gender, among 157 RA patients in remission at
baseline and 1 year
Variable Mean MDHAQ Pain
(95% CI)
P
Disease duration 0.44
≤3 years 1.4 (0.8, 2.0)
4-11 years 1.8 (1.2, 2.4)
≥12 years 1.7 (1.0, 2.4)
Rheumatoid factor/cyclic citrullinated
peptide status
0.59
Seropositive 1.5 (0.9, 2.1)
Seronegative 1.7 (1.2, 2.2)
Tender-joint count 0.79
0 1.6 (1.1, 2.1)
1 1.5 (0.6, 2.4)
≥2 1.8 (0.8, 2.9)
Swollen-joint count 0.92
0 1.6 (1.1, 2.1)
1 1.2 (0.0, 2.3)
≥2 1.7 (1.1, 2.4)
C-reactive protein 0.28
<0.7 mg/L 1.5 (0.9, 2.1)
0.7-2.0 mg/L 1.5 (0.9, 2.1)
≥2.1 mg/L 1.9 (1.3, 2.5)
Patient global health assessment <0.0001
<5 0.6 (0.1, 1.1)
5-14 1.4 (0.8, 1.9)
≥15 2.9 (2.4, 3.4)
Sharp score 0.24
≤1 1.8 (1.1, 2.4)
2-17 1.9 (1.2, 2.7)
≥18 1.2 (0.5, 2.0)
MDHAQ Function Scale <0.0001
0 0.6 (0.1, 1.2)
0.1-0.9 1.4 (0.9, 2.0)
≥1.0 2.9 (2.3, 3.4)
Mental Health Index 5 0.004
≤70 2.2 (1.6, 2.8)
71-80 1.7 (1.1, 2.4)
>80 1.1 (0.6, 1.7)
MDHAQ Fatigue Scale <0.0001
<1.0 0.9 (0.3, 1.4)
1.0-3.9 1.2 (0.7, 1.8)
≥4.0 2.9 (2.3, 3.4)
MDHAQ Sleep Problems Score 0.0005
0 1.2 (0.7, 1.7)
1 2.1 (1.5, 2.7)
≥2 2.7 (1.6, 3.8)
Arthritis Self-Efficacy Score 0.0005
<78 2.1 (1.6, 2.7)
78-87 1.9 (1.3, 2.5)
≥88 0.9 (0.3, 1.4)
Table 2 Cross-sectional associations between baseline
clinical variables and baseline MDHAQ pain, adjusted for
age and gender, among 157 RA patients in remission at
baseline and 1 year (Continued)
Modified Charlson Index 0.91
≤1 1.6 (1.2, 2.1)
>1 1.6 (1.0, 2.2)
MDHAQ, Multi-Dimensional Health Assessment Questionnaire; RA, rheumatoid
arthritis.
P values from multivariable linear regression models.
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DAS28-CRP4 remission.
In recognition that the DAS28-CRP4 remission criter-
ion may be too permissive of residual inflammation, we
also examined the prevalence of clinically significant
pain among patients meeting 2010 ACR/EULAR remis-
sion criteria. The prevalence of clinically significant pain
in this group was much lower, none at baseline and
5.7% at 1 year. This low prevalence is likely due to the
ACR/EULAR criterion limiting the patient global assess-
ment score to ≤1. Because the patient global assessment
is heavily influenced by pain [30], this criterion essen-
tially excludes patients with high pain scores. It is not
clear whether omitting these patients is appropriate
because the ACR/EULAR remission criteria exclude
patients with pain due to residual, undetected inflamma-
tion or is inappropriate because the ACR/EULAR cri-
teria include patients with non-inflammatory causes of
pain. Our data do not allow us to distinguish between
these two possibilities because we do not have measure-
ments of joint tenderness and swelling in the feet and
ankles. We also do not have radiographic measures to
assess subclinical inflammation. Future studies including
detailed assessments of inflammation in the lower extre-
mities and radiographic assessments of synovitis are
needed to elucidate the relation between inflammation
and pain severity among patients in DAS28-CRP4
remission.
An additional limitation of this study is the homoge-
neity of the study population. The study was conducted
at a single academic center, and 93.6% of this population
was Caucasian. Other studies have reported higher rates
of pain among racial minorities [31], and associations
between pain, sleep problems, fatigue, and self-efficacy
may differ depending on race. Future studies are needed
to evaluate these relationships among different
populations.
Conclusions
Pain continues to persist in a substantial subgroup of
patients who meet the DAS28-CRP4 threshold for
remission, whereas nearly all patients with clinically sig-
nificant pain are excluded by the ACR/EULAR
Table 3 Longitudinal associations between baseline
clinical variables and 1-year MDHAQ pain, adjusted for
age, gender, and baseline MDHAQ pain, among 157 RA
patients in remission at baseline and 1 year
Variable Mean MDHAQ Pain
(95% CI)
P
Disease duration 0.02
≤3 years 1.6 (1.1, 2.2)
4-11 years 2.0 (1.6, 2.5)
≥12 years 2.4 (1.8, 3.0)
Rheumatoid factor/cyclic citrullinated
peptide status
0.77
Seropositive 1.9 (1.5, 2.4)
Seronegative 2.1 (1.5, 2.6)
Tender-joint count 0.36
0 2.1 (1.6, 2.5)
1 1.7 (1.0, 2.5)
≥2 1.8 (0.9, 2.6)
Swollen-joint count 0.02
0 2.2 (1.8, 2.6)
1 1.3 (0.3, 2.3)
≥2 1.5 (1.0, 2.1)
C-reactive protein 0.77
<0.7 mg/L 1.9 (1.4, 2.5)
0.7-2.0 mg/L 2.0 (1.5, 2.5)
≥2.1 mg/L 2.0 (1.5, 2.5)
Patient global health assessment 0.03
<5 1.6 (0.9, 2.2)
5-14 1.7 (1.1, 2.2)
≥15 2.5 (2.0, 3.0)
Sharp score 0.53
≤1 2.1 (1.4, 2.7)
2-17 2.2 (1.6, 2.9)
≥18 1.8 (1.1, 2.5)
MDHAQ Function Scale 0.008
0 1.6 (1.0, 2.2)
0.1-0.9 1.5 (1.0, 2.0)
≥1.0 2.7 (2.1, 3.2)
Mental Health Index 5 0.43
≤70 2.2 (1.7, 2.4)
71-80 1.7 (1.1, 2.3)
>80 1.9 (1.4, 2.4)
MDHAQ Fatigue Scale 0.0001
<1.0 1.2 (0.7, 1.8)
1.0-3.9 1.8 (1.3, 2.3)
≥4.0 2.8 (2.3, 3.3)
MDHAQ Sleep Problems Score 0.001
0 1.6 (1.1, 2.0)
1 2.3 (1.8, 2.8)
≥2 3.1 (2.2, 4.0)
Arthritis Self-Efficacy Score 0.01
<78 2.2 (1.7, 2.7)
78-87 2.3 (1.8, 2.8)
≥88 1.4 (0.9, 1.9)
Table 3 Longitudinal associations between baseline clini-
cal variables and 1-year MDHAQ pain, adjusted for age,
gender, and baseline MDHAQ pain, among 157 RA
patients in remission at baseline and 1 year (Continued)
Modified Charlson Index 0.35
≤1 1.9 (1.5, 2.3)
>1 2.2 (1.6, 2.7)
MDHAQ, Multi-Dimensional Health Assessment Questionnaire; RA, rheumatoid
arthritis. P values are from multivariable linear regression models.
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Page 7 of 9remission criteria. Among RA patients who meet the
DAS28-CRP4 threshold for remission, pain was not
associated with inflammatory markers and did not
diminish despite continued control of inflammation over
a 1-year period. Pain was associated with fatigue, sleep
problems, and self-efficacy. These findings stress the
importance of assessing alternative causes of pain and
modifying therapy to address specific modulators of
pain, rather than assuming that pain is an indicator of
inflammation that should be treated by increasing
immunosuppressive therapies.
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